Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Neurological conditions

Early intensive therapy may delay MS progression

Researchers have shown that early high-efficacy therapy with monoclonal antibodies offers better long-term outcomes compared with moderate-efficacy therapy for people living with multiple sclerosis.

igg monoclonal antibody


Monoclonal antibody therapies for people with multiple sclerosis are often reserved for patients deemed at greatest risk of disease progression

Early aggressive therapy for multiple sclerosis (MS) is associated with improved long-term outcomes compared with an escalation approach, a study in JAMA Neurology (online, 18 February 2019) has shown[1].

The research used data on 592 patients diagnosed with MS in South East Wales who first received disease-modifying therapy (DMT) between 1998 and 2016.

Over the first five years of starting DMT, the change in expanded disability status score (measured from 0–10) was significantly less in patients that were initiated on high-efficacy treatment (monoclonal antibodies), compared with those who commenced treatment on a moderate-efficacy DMT (+0.3 vs. +1.2).

The researchers explained that monoclonal antibody therapies were often reserved for patients deemed at greatest risk of disease progression, largely owing to concerns over safety. However, they added that this approach had not been verified in randomised trials and mechanisms may not be in place to detect treatment failure quickly enough.

“Our study undermines the prevalent belief that an escalation approach represents a lower-risk strategy to MS treatment and suggests that in the real world, an escalation approach to DMT may be inadequate to prevent unfavourable long-term outcomes,” they concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206298

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.